Delphia Therapeutics
27 employees
Biotech/Pharma
Series A · $67.0M
Open positions (2)
Company details
Team Size27
IndustryBiotech/Pharma
Funding
Total raised
$67.0M
Last stage
Series A
Investors
Polaris Innovation Fund
Total raised
$67.0M
Last stage
Series A
Investors
Bill Sellers
Director of the cancer program at the Broad Institute of MIT and Harvard; led breakthrough research on activation lethality underlying Delphia's platform.
Mike Dillon
Former Chief Scientific Officer of IDEAYA Biosciences and former global head of discovery chemistry for oncology at Novartis Institutes for Biomedical Research (NIBR).
Kevin Marks
Two decades of experience as a cancer drug hunter; former head of oncology drug discovery at Novartis Institutes for Biomedical Research (NIBR) and head of biology at Agios Pharmaceuticals; co-founded Delphia in 2022 as entrepreneur-in-residence at GV.
LinkedInNo applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.